Alkermes plc (NASDAQ:ALKS - Free Report) - Stock analysts at Zacks Research dropped their Q2 2025 EPS estimates for shares of Alkermes in a note issued to investors on Wednesday, October 9th. Zacks Research analyst R. Department now anticipates that the company will post earnings per share of $0.44 for the quarter, down from their prior estimate of $0.45. The consensus estimate for Alkermes' current full-year earnings is $2.36 per share. Zacks Research also issued estimates for Alkermes' Q3 2025 earnings at $0.50 EPS, Q4 2025 earnings at $0.51 EPS, FY2025 earnings at $1.84 EPS, Q2 2026 earnings at $0.56 EPS, Q3 2026 earnings at $0.59 EPS and FY2026 earnings at $2.03 EPS.
Alkermes (NASDAQ:ALKS - Get Free Report) last posted its earnings results on Wednesday, July 24th. The company reported $0.70 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.70. Alkermes had a net margin of 19.15% and a return on equity of 23.20%. The business had revenue of $399.13 million for the quarter, compared to analyst estimates of $393.30 million. During the same period last year, the business posted $0.38 EPS. Alkermes's revenue was down 35.4% compared to the same quarter last year.
Other analysts have also issued reports about the stock. Robert W. Baird raised their price target on shares of Alkermes from $37.00 to $38.00 and gave the stock an "outperform" rating in a research report on Thursday, July 25th. StockNews.com upgraded shares of Alkermes from a "hold" rating to a "buy" rating in a research report on Sunday, July 28th. TD Cowen initiated coverage on shares of Alkermes in a research report on Monday, June 17th. They set a "buy" rating and a $34.00 target price on the stock. Cantor Fitzgerald reiterated an "overweight" rating and set a $48.00 target price on shares of Alkermes in a research report on Thursday. Finally, JPMorgan Chase & Co. lifted their target price on shares of Alkermes from $31.00 to $32.00 and gave the company a "neutral" rating in a research report on Thursday, July 25th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $36.70.
Check Out Our Latest Stock Report on ALKS
Alkermes Stock Performance
NASDAQ:ALKS traded up $0.14 during midday trading on Monday, reaching $29.05. The stock had a trading volume of 2,029,692 shares, compared to its average volume of 1,833,830. The company has a debt-to-equity ratio of 0.22, a current ratio of 2.99 and a quick ratio of 2.61. The stock has a market capitalization of $4.92 billion, a P/E ratio of 11.48, a PEG ratio of 0.56 and a beta of 0.46. The firm's fifty day simple moving average is $27.64 and its 200-day simple moving average is $25.79. Alkermes has a 1-year low of $22.01 and a 1-year high of $32.88.
Institutional Investors Weigh In On Alkermes
Several institutional investors have recently modified their holdings of ALKS. Price T Rowe Associates Inc. MD grew its position in shares of Alkermes by 421.8% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 8,326,256 shares of the company's stock worth $225,393,000 after buying an additional 6,730,671 shares during the period. Wellington Management Group LLP lifted its holdings in Alkermes by 29.8% during the fourth quarter. Wellington Management Group LLP now owns 15,241,470 shares of the company's stock worth $422,798,000 after acquiring an additional 3,494,678 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Alkermes by 12.3% during the fourth quarter. Vanguard Group Inc. now owns 20,955,454 shares of the company's stock worth $581,304,000 after acquiring an additional 2,288,185 shares in the last quarter. Armistice Capital LLC increased its holdings in shares of Alkermes by 301.5% in the second quarter. Armistice Capital LLC now owns 2,699,179 shares of the company's stock worth $65,050,000 after acquiring an additional 2,026,961 shares in the last quarter. Finally, Pacer Advisors Inc. raised its holdings in Alkermes by 31.8% during the 2nd quarter. Pacer Advisors Inc. now owns 5,640,642 shares of the company's stock worth $135,939,000 after buying an additional 1,362,079 shares during the period. Institutional investors and hedge funds own 95.21% of the company's stock.
About Alkermes
(
Get Free Report)
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.
Featured Articles
Before you consider Alkermes, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alkermes wasn't on the list.
While Alkermes currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
